First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

Critical Reviews in Oncology/Hematology

Volumn 77, Issue 1, 2011, Pages 78-84

  Sastre, J ^a   Aranda, E ^b   Gravalos C ^c   Massuti B ^d   Varella Garcia, M ^e   Rivera, F ^f   Soler, G ^g   Carrato, A ^h   Manzano, J L ⁱ   Diaz Rubio E ^a   Hidalgo, M ^j  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j Centro Integral Oncologico Clara Campal   (Spain)

more..

Author keywords

Cetuximab; Colorectal cancer; EGFR; Elderly patients; Monotherapy

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; IRINOTECAN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

AGED; ANOREXIA; ASTHENIA; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULITIS; GENE DOSAGE; GERIATRIC PATIENT; HUMAN; MALE; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; REVIEW; SKIN TOXICITY; SPAIN; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPAIN;

EID: 78650309129     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.11.005     Document Type: Review

References (30)

1. Gatta G., Faivre J., Capocaccia R., et al. Survival of colorectal cancer patients in Europe during period 1978-1989. Eur J Cancer 1998, 44:27-42.
2. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
3. Feliu J., González Barón M., Espinosa E., et al. Uracil and tegafur modulated with leucovorin. An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 1997, 79:1884-1889.
4. Feliu J., Mel J.R., Camps C., et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur J Cancer 2002, 38:1204-1211.
5. Abad A., Aranda E., Navarro M., et al. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer. Rev Oncol 2000, 2:154-158.
6. Sastre J., Marcuello E., Masutti B., et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. J Clin Oncol 2005, 23:3545-3551.
7. Feliu J., Salud A., Escudero P., et al. XELOX (Capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006, 94:969-975.
8. Mitry E., Douillard J.Y., Van Cutsem E., et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004, 15:1013-1017.
9. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24:4085-4091.
10. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224-237.
11. Honecker F., Köhne C.-H., Bokemeyer C. Colorectal cancer in the elderly. Is palliative chemotherapy of value?. Drugs Aging 2003, 20:1-11.
12. Goldstein N.I., Prewett M., Zulys K., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318.
13. Saltz L.B., Meropol N.J., Loehrer P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
14. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
15. Vogel C.L., Cobliegh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overxpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
16. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
17. Van Cutsem E., Lang I., Dóhaens G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRIwith or without cetuximab: the CRYSTAL experience. Proc Am Soc Clin Oncol 2008, 26. [abstract 2].
18. Gregorc V., Hidalgo M., Spreafico A., et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 2008, 83:477-484.
19. Jimeno A., Daw N.C., Amador M.L., et al. Analysis of biologic surrogate markers from Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer 2007, 49:352-357.
20. Jimeno A., Rubio-Viqueira B., Amador M.L., et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005, 65:3003-3010.
21. Malik S.N., Bedolla R.G., Hidalgo M., et al. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples. Methods Mol Med 2003, 85:135-140.
22. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26:3351-3357.
23. Pessino A., Artale S., Sciallero S., et al. First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol 2008, 18:711-716.
24. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
25. Jonker D., OóCallaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
26. Chung K.Y., Shia J., Kemmeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23:1803-1810.
27. Amado R.G., Wolf M., Freeman D., et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. ECCO-14 the european cancer conference 2007, [abstract 7LB#].
28. Finocchiaro G., Cappuzzo F., Jänne P.A., et al. EGFR, HER2 and KRAS as predicitve factors for cetuximab sensitivity in colorectal cancer. Proc Am Soc Clin Oncol 2007, 25.. [abstract 4021].
29. Personeni N., Fieuws S., Piessevaux H., et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer treated with cetuximab: a fluorescent in situ Hybridization study. Clin Cancer Res 2008, 14:5869-5876.
30. Capuzzo F., Varella-Garcia M., Finocchiaro G., et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008, 99:83-89.